21.02. – 22.02.
Over 250 delegates representing leading biotech companies, global pharma organisations and internationally renowned academic institutions Over 55 presentations, case studies, round-table and panel discussions focused on the key innovations of biomarker research in discovery and development, companio
22.02. – 23.02.
Technology in RNA interference, oligonucleotides and mRNA has revolutionised the way infectious disease, cancer and neurological disorders are treated. It is now possible to target previously ‘un-druggable’ sites, therefore expanding the range of therapeutics that selectively silence genes before th
24.02. – 27.02.
A significant challenge in clinical medicine, particularly in cancer and neurodegenerative disease, is the absence of pharmaceuticals that directly target the pathology. In cancer, well over 90% of mutations found in patient tumors are deemed ‘non-actionable’. Many proteins with ‘non-actionable’ mut